Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...